Epigral Reports March 2024 Consolidated Sales at Rs 524.63 Crore, Slight Profit Rise

Epigral, a key player in its industry, released its consolidated financial results for the quarter ending March 2024. The company's net sales stood at Rs 524.63 crore, marking a decline of 6.68% compared to Rs 562.18 crore recorded during the same quarter the previous year. Despite this drop in revenue, Epigral managed to slightly increase its net profit by 0.71%, reporting Rs 77.28 crore against Rs 76.73 crore in March 2023.

Looking closer at the company's earnings before interest, taxes, depreciation, and amortization (EBITDA), the figure dipped by 1.43% to Rs 156.92 crore from Rs 159.20 crore a year earlier. Earnings per share (EPS) grew modestly, reaching Rs 18.60 in the recent quarter compared to Rs 18.47 in March 2023, reflecting steady shareholder value amidst fluctuating sales.

Epigral's stock performance has been notable over recent periods. Shares closed at Rs 1,398.90 on the National Stock Exchange on April 22, 2024. Over the past six months, the stock has appreciated by 53.14%, and it has delivered a 33.33% return in the last twelve months. These figures suggest investor confidence despite the slight contraction in sales.

The detailed financial breakdown reveals that raw material consumption decreased to Rs 272.88 crore from Rs 336.82 crore year-on-year, indicating possible efficiency improvements or shifts in procurement. Employee costs rose marginally to Rs 25.52 crore, while depreciation expenses remained consistent at around Rs 30 crore. Other operating expenses stayed stable at approximately Rs 77 crore.

Profit before other income, interest, exceptional items, and taxes improved to Rs 125.02 crore, up from Rs 124.53 crore a year earlier. However, other income declined to Rs 1.52 crore from Rs 4.54 crore, a factor that slightly tempered overall profitability. Interest expenses also fell to Rs 13.69 crore from Rs 18.99 crore, helping to support the net profit growth.

Tax payments rose to Rs 36.18 crore from Rs 33.33 crore, reflecting the higher pre-tax profits. The company reported no exceptional or extraordinary items for this quarter, making the net profit a close reflection of operational performance.

Epigral’s consolidated equity share capital remains steady at Rs 41.55 crore. The company did not declare an equity dividend rate for this quarter. Shareholding details regarding promoters and promoter groups were not disclosed.

Epigral operates in a competitive market where fluctuations in raw material costs and changing demand patterns can impact revenue figures. The marginal increase in profits alongside a dip in sales suggests the company has managed costs effectively. This financial discipline could position Epigral well for future growth as market conditions evolve.

Industry analysts often look at such quarterly results to gauge how companies are navigating economic challenges and opportunities. For investors, the steady EPS growth and stock performance may signal confidence in Epigral's strategic direction and operational resilience.

Overall, while the decline in net sales is a point of attention, the company's ability to maintain profitability and deliver solid returns to shareholders highlights a balanced financial standing. Market watchers will likely monitor Epigral’s upcoming quarters to assess if these trends continue.